- Conditions
- Healthy Volunteer
- Interventions
- ETEC strain B7A (O148:H28 CS6+ LT+ST+) (Lot 0481) in Buffer
- Biological
- Lead sponsor
- Johns Hopkins Bloomberg School of Public Health
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 73–90
of 90
matching trials from the live ClinicalTrials.gov search.
- Conditions
- E. Coli Infection, Multi-antibiotic Resistance
- Interventions
- Not listed
- Lead sponsor
- Ann & Robert H Lurie Children's Hospital of Chicago
- Other
- Eligibility
- Female only
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Shigella
- Interventions
- SF2a-TT15 Shigella Vaccine, Placebo, S. flexneri 2a strain 2457T Challenge Agent
- Biological · Other
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 58 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Diarrhea
- Interventions
- Invaplex[AR-DETOX], Placebo
- Biological · Other
- Lead sponsor
- PATH
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 58 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Silver Spring, Maryland
- Conditions
- Infection, E Coli Infections, Klebsiella Infections, Proteus Infections
- Interventions
- Not listed
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- Not listed
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2015
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Risk Reduction
- Interventions
- Vivotif Typhoid Oral Vaccine
- Drug
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004 – 2030
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Shigella
- Interventions
- CVD 1208S, a Shigella flexneri 2a live, oral vaccine, Placebo
- Biological · Other
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland
- Conditions
- E Coli Infections, Allogenic Transplant Patients
- Interventions
- SNIPR001 consists of genetically modified bacteriophages specifically targeting Escherichia coli, Placebo 10 mL
- Biological · Other
- Lead sponsor
- SNIPR Biome Aps.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 10
- States / cities
- Duarte, California • San Francisco, California • Baltimore, Maryland + 6 more
- Conditions
- E Coli Infection
- Interventions
- no Intervention
- Other
- Lead sponsor
- Duke University
- Other
- Eligibility
- Not listed
- Enrollment
- 300 participants
- Timeline
- 2020 – 2021
- U.S. locations
- 13
- States / cities
- Torrance, California • Aurora, Colorado • Atlanta, Georgia + 10 more
- Conditions
- Urinary Tract Infections
- Interventions
- LBP-EC01 0.1 x IV dose, LBP-EC01 0.01x IV Dose, LBP-EC01 IV Infusion Dose, Placebo, LBP-EC01, TMP/SMX
- Drug
- Lead sponsor
- Locus Biosciences
- Industry
- Eligibility
- 18 Years to 75 Years · Female only
- Enrollment
- 318 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 17
- States / cities
- Fresno, California • Lancaster, California • Los Angeles, California + 13 more
- Conditions
- Shigella
- Interventions
- ShigETEC vaccine, Placebo, Challenge: Shigella flexneri 2457T at a dose of 1.5x10^3 CFU
- Biological · Other
- Lead sponsor
- Eveliqure Biotechnologies GmbH
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Typhoid Fever
- Interventions
- Ty800 (Salmonella typhi) Oral Vaccine
- Biological
- Lead sponsor
- Avant Immunotherapeutics
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 180 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2008
- U.S. locations
- 5
- States / cities
- San Diego, California • Melbourne, Florida • Peoria, Illinois + 2 more
- Conditions
- Gastroenteritis Escherichia Coli, Immunisation
- Interventions
- Placebo, Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral enterotoxigenic Escherichia coli (ETEC) Vaccine
- Other · Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Diarrhea
- Interventions
- Rifaximin
- Drug
- Lead sponsor
- Bausch Health Americas, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 660 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2008
- U.S. locations
- 3
- States / cities
- South Miami, Florida • Houston, Texas • La Porte, Texas
- Conditions
- Shigella Infection, Enterotoxigenic Escherichia Coli Infection
- Interventions
- strain CVD 1208S-122, Placebo
- Biological · Other
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 53 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Shiga Toxin-Producing Escherichia Coli (E. Coli) Infection, Hemolytic-Uremic Syndrome
- Interventions
- Infusion of 200% maintenance fluids as balanced crystalloid IV solution, Oral fluids; infusion of up to 110% maintenance fluids as balanced crystalloid IV solution
- Other
- Lead sponsor
- University of Calgary
- Other
- Eligibility
- 9 Months to 21 Years
- Enrollment
- 1,040 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 19 more
- Conditions
- Antimicrobial Drug Resistance, Antibiotic Resistant Infection, Clostridium Difficile, Carbapenem-Resistant Enterobacteriaceae Infection, Extended Spectrum Beta-Lactamase Producing Bacteria Infection, Vancomycin Resistant Enterococci Infection, Carbapenem Resistant Bacterial Infection, Vancomycin-Resistant Enterococcal Infection
- Interventions
- Not listed
- Lead sponsor
- The Methodist Hospital Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2026
- U.S. locations
- 2
- States / cities
- Houston, Texas
- Conditions
- Healthy Volunteer
- Interventions
- Anti CS6 BSIgG product (Lot PD1601105CS), Anti B7A BSIgG product (Lot PD1601132ET), Bovine Immunoglobin Negative Control (Lot PD161071NC), B7A- CS6-expressing ETEC challenge strain
- Biological
- Lead sponsor
- Johns Hopkins Bloomberg School of Public Health
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland